{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=6", "query": { "intervention": "Investigator's Treatment of Choice", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 245, "total_pages": 25, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Investigator%27s+Treatment+of+Choice&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T20:32:37.098Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01446159", "title": "Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer" ], "interventions": [ { "name": "MEDI-573", "type": "DRUG" }, { "name": "Aromatase Inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 188, "start_date": "2011-06-13", "completion_date": "2019-06-28", "has_results": true, "last_update_posted_date": "2020-06-02", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 34, "location_summary": "Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01446159" }, { "nct_id": "NCT04658862", "title": "A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Cetrelimab", "type": "BIOLOGICAL" }, { "name": "TAR-200", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Conventional radiation therapy", "type": "RADIATION" }, { "name": "Hypo-fractioned radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2020-12-07", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 28, "location_summary": "Loma Linda, California • Los Angeles, California • Santa Monica, California + 25 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04658862" }, { "nct_id": "NCT04585477", "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage I", "Non-small Cell Lung Cancer Stage II", "Non-small Cell Lung Cancer Stage III" ], "interventions": [ { "name": "AVENIO ctDNA Surveillance Kit", "type": "DEVICE" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2021-04-08", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585477" }, { "nct_id": "NCT07174336", "title": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "LY4064809", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2025-12-22", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 129, "location_summary": "Anchorage, Alaska • Chandler, Arizona • Phoenix, Arizona + 110 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07174336" }, { "nct_id": "NCT01482962", "title": "Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed Peripheral T-Cell Lymphoma", "Refractory Peripheral T-Cell Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Pralatrexate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2012-06-11", "completion_date": "2017-12-18", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 24, "location_summary": "Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482962" }, { "nct_id": "NCT06708897", "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CLL / SLL", "CLL (Chronic Lymphocytic Leukemia)", "SLL (Small Lymphocytic Lymphoma)", "Marginal Zone Lymphoma(MZL)", "Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia" ], "interventions": [ { "name": "Lonitoclax (ZE50-0134)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lomond Therapeutics Holdings, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2025-04-08", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 5, "location_summary": "Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Louisville", "state": "Kentucky" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06708897" }, { "nct_id": "NCT05608044", "title": "A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 234, "start_date": "2022-11-30", "completion_date": "2029-09", "has_results": false, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 26, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608044" }, { "nct_id": "NCT03765918", "title": "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Neoplasms" ], "interventions": [ { "name": "Pembrolizumab 200 mg", "type": "BIOLOGICAL" }, { "name": "Radiotherapy 60 Gray", "type": "RADIATION" }, { "name": "Radiotherapy 66 Gray", "type": "RADIATION" }, { "name": "Radiotherapy 70 Gray", "type": "RADIATION" }, { "name": "Cisplatin 100 mg/m^2", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 714, "start_date": "2018-12-17", "completion_date": "2026-11-17", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 68, "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 56 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03765918" }, { "nct_id": "NCT04958642", "title": "Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Niemann-Pick Disease, Type C" ], "interventions": [ { "name": "Adrabetadex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mandos LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "4 Years to 21 Years" }, "enrollment_count": 66, "start_date": "2015-12-23", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-08-29", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04958642" }, { "nct_id": "NCT04975308", "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 874, "start_date": "2021-10-04", "completion_date": "2027-08", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-13T20:32:37.098Z", "location_count": 48, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975308" } ] }